RxDoctor Payments Data

Lisa Gleason, MD

Clinical Cardiac Electrophysiology · del Mar, CANPI 1700865045

Payments from drug & device makers

$13,086in general payments, 2019–2025

Across 77 payments — averaging $169.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$9K
  • Biosense Webster, Inc.$2K
  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$515
  • Cardiva Medical, Inc.$48
  • Medtronic$32
  • plus $68 from 4 others

What the payments were for

  • Consulting fees$11,25086%
  • Travel & lodging$90%
  • Food & beverage$1,82714%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,086 in reported general payments places this provider in the 20th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$120,799
Medicare patients
798
Services billed
1,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban284$346,162
XareltoRivaroxaban180$226,100
EntrestoSacubitril/Valsartan39$41,435
MultaqDronedarone Hcl27$34,669
Repatha PushtronexEvolocumab12$18,297
FarxigaDapagliflozin Propanediol11$12,226
Dabigatran EtexilateDabigatran Etexilate Mesylate32$6,909
Flecainide Acetate93$4,049
Metoprolol Succinate209$3,857
Amiodarone Hcl140$2,914
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$2,138
Verapamil SrVerapamil Hcl11$1,371
Atorvastatin Calcium83$965
Losartan Potassium112$775
Bumetanide17$760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$13$12,22611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in del Mar

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →